A 43% HiSCR75 response rate and a 29-percentage-point delta versus placebo at week 12 are not numbers MoonLake inherited from a crowded field — they are the highest efficacy figures ever recorded in an adequate and well-controlled hidradenitis suppurativa trial. That clinical ceiling matters enormously for what comes next, because the FDA has now formally agreed those MIRA trial figures belong on the sonelokimab label, resolving the most consequential uncertainty that had shadowed the program since MIRA’s design diverged from the VELA trials.
The pre-BLA alignment covers more ground than the headline efficacy numbers suggest. FDA accepted the VELA-TEEN adolescent data as final and pivotal at time of BLA submission, meaning sonelokimab enters review with a proposed label spanning patients aged 12 and above — a population no currently approved HS biologic reaches cleanly at launch. Priority Review designation is now being formally pursued on the strength of that pediatric inclusion, which would compress the standard 12-month clock to roughly 6 months once accepted. Chemistry, Manufacturing, and Controls were cleared without gap items, removing the manufacturing risk that has derailed late-stage filings for other biologics. The BLA goes in at end of September; the FDA’s 60-day filing decision arrives by November; commercial launch targets the second half of 2027.
The financial picture is functional rather than comfortable. MoonLake held $357.9 million in cash at March 31, with a runway projected to end of 2027 — tight against a launch timeline that lands in the same window. The $400 million Hercules debt facility exists precisely for that gap, but drawing on it ahead of approval will be a deliberate decision that management has not yet had to make. R&D spend held roughly flat quarter-over-quarter at $54.5 million, while G&A jumped $6.3 million largely due to accelerated stock option expense from voluntary award cancellations — an internal compensation restructuring that has no bearing on the clinical program but signals organizational tidying ahead of a pivotal 18 months.
The single readout that will define sonelokimab’s commercial trajectory before the BLA even lands is the IZAR-1 Phase 3 primary endpoint in psoriatic arthritisarthritis, expected mid-2026. A positive result transforms MoonLake from a single-indication story into a multi-indication IL-17A/F platform at the exact moment regulators are evaluating the HS filing — that sequencing either amplifies or complicates the investment thesis in ways that dwarf any label negotiation already completed.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
